Orion Oyj (OTCMKTS:ORINY) Raises Dividend to $0.45 Per Share

Orion Oyj (OTCMKTS:ORINY) declared a dividend on Monday, March 17th, NASDAQ Dividends reports. Investors of record on Monday, April 7th will be given a dividend of 0.4478 per share on Tuesday, April 29th. The ex-dividend date is Monday, April 7th. This is a 86.2% increase from Orion Oyj’s previous dividend of $0.24.

Orion Oyj Price Performance

OTCMKTS ORINY remained flat at $29.76 on Tuesday. 115 shares of the company’s stock traded hands, compared to its average volume of 3,410. The stock’s fifty day simple moving average is $26.81 and its 200-day simple moving average is $25.49. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.41 and a current ratio of 2.42. Orion Oyj has a 1 year low of $17.50 and a 1 year high of $30.25. The company has a market capitalization of $8.40 billion, a price-to-earnings ratio of 23.62 and a beta of 0.25.

Orion Oyj (OTCMKTS:ORINY) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.28 EPS for the quarter. The company had revenue of $463.41 million for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. On average, equities analysts expect that Orion Oyj will post 1.18 EPS for the current year.

Analysts Set New Price Targets

Separately, Nordea Equity Research cut shares of Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.